Skip to main content

Table 3 Model parameters used in the base case analysis and distributions used for the sensitivity analysis

From: Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer

Description Value Distribution Sources
Utilities
 Remission (R) 0.94 Beta (89, 6) [42, 43]
 Local recurrence (LR) 0.82 Beta (77, 23) [16]
 Distant recurrence (DR) 0.58 Beta (171, 79) [16]
Transition probabilities
 R > LR 0.029 Beta (27, 983) [26]
 R > DR 0.087 Beta (102, 1061) [15, 16]
 LR > R 0.1 Beta (111, 899) [16]
 LR > DR 0.261 Beta (119, 931) [16]
 DR > BCD 0.325 Beta (15, 20) [16]
 R, DR, LR > D All-cause mortality Age-specific mortality [32]
 Hazard ratio years 1–5 0.59 Log-Normal (− 0.527, 0.089) [16, 44]